Development of a customized diagnostic test for lung cancer

多胺途径已被证明在癌细胞中显著上调。我们的行业合作伙伴BioMark Diagnostics Inc.的初步研究表明，多胺途径的代谢物可能成为肺癌的强有力的诊断生物标志物。在我们之前资助的NSERC Engage项目中，我们用液相色谱-质谱仪(LC-MS)分析了肺癌中的多胺代谢物。还测定了许多其他代谢物，包括脂质、生物胺和氨基酸。生物信息学和统计分析表明，与多胺代谢物单独提供的敏感性和特异性相比，纳入这些额外的代谢物中的4种提高了诊断肺癌的敏感性和特异性。基于这项工作和与BioMark的咨询，我们已经确定了13个能够区分对照(健康)和肺癌样本的代谢物生物标记物。

The polyamine pathway has been demonstrated to be significantly up-regulated in cancer cells. Preliminary studies by our industry collaborator, BioMark Diagnostics Inc, have indicated that metabolites of the polyamine pathway may serve as robust diagnostic biomarkers for lung cancer. In our previously funded NSERC Engage project, we measured polyamine metabolites in lung cancer by liquid chromatography-mass spectrometry (LC-MS) analysis. A number of other metabolites were also measured, including lipids, biogenic amines, and amino acids. Bioinformatics and statistical analysis revealed that the inclusion of 4 of these additional metabolites increased the sensitivity and specificity for diagnosing lung cancer compared to the sensitivity and specificity provided by the polyamine metabolites alone. Based on this work and consultation with BioMark, we have identified 13 metabolite biomarkers that were able to distinguish between control (healthy) and lung cancer samples.